Roche Continues its Fight Against Mpox

Roche Responds to WHO Global Health Emergency

Roche, a global pharmaceutical company, is proud to support the international effort against the mpox global health emergency by providing access to its diagnostic tests. These tests are used to rapidly identify the virus, allowing healthcare providers to isolate and treat patients, and prevent the further spread of the mpox virus. Roche's tests are highly accurate and sensitive, which is crucial for effective mpox management and control. Roche's commitment to combating mpox is a testament to its dedication to global health and well-being.

Roche's Commitment to Addressing Mpox

Roche has been actively engaged in addressing the mpox emergency since its outbreak. The company has collaborated with healthcare providers and governments worldwide to ensure that its diagnostic tests are accessible to those who need them. Roche has also supported research and development efforts to further understand the virus, its transmission, and potential treatments.

Roche's continued support in addressing the global mpox emergency is a reflection of its commitment to public health and its dedication to supporting healthcare providers on the front lines of this fight.

About Roche

Roche is a global healthcare company that develops and provides innovative diagnostics, pharmaceuticals, and personalized healthcare solutions. The company is headquartered in Basel, Switzerland, and operates in over 100 countries worldwide. Roche is dedicated to improving patient outcomes, advancing scientific knowledge, and contributing to society.